T. Shang

Single in situ intratumoral low-dose shikonin hydrogel plus mild photothermal therapy elicits systemic antitumor immunity in immune-cold triple-negative breast cancer

Shikonin (SHK) possesses potent antitumor activity; however, its severe non-selective toxicity greatly limits the feasibility of conventional systemic administration for cancer therapy. Likewise, mild photothermal therapy (PTT) has intrinsic limitations, including inadequate induction of immunogenic cell death (ICD) an...